The Firm recently represented the underwriters, led by Barclays Bank PLC, Citigroup Global Markets Europe AG and Société Générale, in connection with the public offering by American Medical Systems Europe B.V. of €2 billion of debt securities, fully and unconditionally guaranteed by Boston Scientific Corporation (“Boston Scientific”), consisting of €750 million of 3.375% Senior Notes due 2029 and €1.25 billion of 3.5% Senior Notes due 2032. Boston Scientific intends to use the net proceeds from the offering, together with borrowings under its commercial paper program and cash on hand, to finance the purchase price of its previously announced agreement to acquire Axonics, Inc. and to pay related fees and expenses and, to the extent that the net proceeds from the offering of the Notes are not used for such purposes, to fund the repayment at maturity of its 3.45% senior notes due March 2024 and to pay accrued and unpaid interest with respect to such notes, and for general corporate purposes.
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, Boston Scientific advances science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Boston Scientific’s portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.
The Simpson Thacher team for the transaction included Roxane Reardon, Patrick Baron, Kelly Johnson and J. Carr Gamble (Capital Markets); Jonathan Cantor and Edward Grais (Tax); Marisa Geiger and Rachelle Broida (Intellectual Property); Vanessa Burrows and Nawa Lodin (Healthcare); Michael Isby (Environmental); Jeanne Annarumma (ECEB); and Jennie Getsin (FINRA/Blue Sky).